Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT): a Single-arm, Open-label Phase I/IIa Trial.

Next Previous
Trial Profile

Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT): a Single-arm, Open-label Phase I/IIa Trial.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Catequentinib (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TALENT; TAXE-GC

Most Recent Events

  • 26 Jun 2025 Status changed from recruiting to completed.
  • 21 Jan 2023 Interim results (N=38) assessing the safety and efficacy of tislelizumab combined with anlotinib and XELOX (TAXE regimen) as first line treatment for advanced gastric/Gastroesophageal Junction Carcinoma (GC/GEJC) , presented at the 2023 Gastrointestinal Cancers Symposium.
  • 20 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top